Chronic sildenafil in men with diabetes and erectile dysfunction

Bibliography

• LEWIS RW, FUGL-MEYER KS, BOSCH R et al.: Definitions, Classification and epidemiology of Sexual Dysfunction. In: Sexual Medicine. Sexual dysfunctions in men and women. Lue TF, Basson R, Rosen R, Giuliano F, Khoury S, Montorsi F (Eds), Plymbridge Distributors Ltd, Plymouth, UK (2004):37-72.
   Google Scholar
• AVERSA A, PILI M, FABBRI A, SPERA E, SPERA G: Erectile dysfunction: expectations beyond phosphodiesterase type 5 inhibition. J. Endocrinol. Invest. (2004) 27:192-206.
   PubMed Web of Science ®Google Scholar
• KANNEL WB, MCGEE DL: Diabetes and cardiovascular disease: the Framingham Study. JAMA (1979) 241:2035-2038.
   PubMed Web of Science ®Google Scholar
• HAFFNER SM, LEHTO S, RONNEMAA T, PYORALA K, LAAKSO M: Mortality from coronary heart disease in subjects with Type 2 diabetes and in non diabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. (1998) 339:229-234.
   PubMed Web of Science ®Google Scholar
• GRUNDY SM, BENJAMIN IJ, BURKE GL et al.: Diabetes and cardiovascular disease: a statement for health professionals from the American Heart Association. Circulation (1999) 100:1134-1146.
   PubMed Web of Science ®Google Scholar
• CUMMINGS MH: Erectile dysfunction in diabetes mellitus. In: International Textbook of Diabetes Mellitus, vol. II. DeFronzo RA, Ferrannini E, Keen H, Zimmet P (Eds), John Wiley & Sons Ltd., West Sussex, UK (2004):1333-1342.
   Google Scholar
• BULTRINI A, CAROSA E, COLPI EM et al.: Possible correlation between Type 1 diabetes mellitus and female sexual dysfunction: case report and literature review. J. Sex Med. (2004) 1(3):337-340.
   PubMed Web of Science ®Google Scholar
• SAIRAM K, KULINSKAYA E, BOUSTEAD GB, HANBURY DC, MCNICOLAS TA: Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int. (2001) 88:68-71.
   PubMed Web of Science ®Google Scholar
• BACON CG, HU FB, GIOVANNUCCI E, GLASSER DB, MITTLEMAN MA, RIMM EB: Association of type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care (2002) 25(8):1458-1463.
   PubMed Web of Science ®Google Scholar
• FEDELE D, BORTOLOTTI A, COSCELLI C et al.: Erectile dysfunction in Type 1 and Type 2 diabetics in Italy. On behalf of Gruppo Italiano Studio Deficit Erettile nei Diabetici. Int. J. Epidemiol. (2000) 29(3):524-531.
   PubMed Web of Science ®Google Scholar
• PANZA JA, QUYYUMI AA, BRUSH JE, EPSTEIN SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N. Engl. J. Med. (1990) 323:22-27.
   PubMed Web of Science ®Google Scholar
• SCHACHINGER V, BRITTEN MB, ZEIHER AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation (2000) 101:1899.
   PubMed Web of Science ®Google Scholar
• VITALE C, MERCURO G, CORNOLDI A, FINI M, VOLTERRANI M, ROSANO GM: Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. (2005) 258(3):250-256.
   PubMed Web of Science ®Google Scholar
• AVERSA A, GRECO E, BRUZZICHES R, PILI M, ROSANO G, SPERA G: Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int. J. Impot. Res. (2007) 18(2):200-207.
   Google Scholar
• GOLDSTEIN I, LUE TF, PADMA-NATHAN H, ROSEN RC, STEERS WD, WICKER PA: Oral sildenafil in the treatment of erectile dysfunction. N. Engl. J. Med. (1998) 338:1397-1404.
   PubMed Web of Science ®Google Scholar
• BALLARD SA, GINGELL CJ, TANG K, TURNER LA, PRICE ME, NAYLOR AM: Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J. Urol. (1998) 159:2164-2171.
   PubMed Web of Science ®Google Scholar
• BOOLELL M, ALLEN MJ, BALLARD SA et al.: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int. J. Impot. Res. (1996) 8:47-52.
   PubMedGoogle Scholar
• BEAVO JA: Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol. Rev. (1995) 75:725-748.
   PubMed Web of Science ®Google Scholar
• RENDELL MS, RAJFER J, WICKER PA, SMITH MD: Sildenafil for the treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA (1999) 281:421-426.
   PubMed Web of Science ®Google Scholar
• CERIELLO A, ASSALONI R, DA ROS R et al.: Effect of atorvastatin and irbesartan, alone and in combination, on postprandial endothelial dysfunction, oxidative stress, and inflammation in Type 2 diabetic patients. Circulation (2005) 111(19):2518-2524.
   PubMed Web of Science ®Google Scholar
• BEHR-ROUSSEL D, GORNY D, MEVEL K et al.: Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur. Urol. (2005) 47(1):87-91.
   PubMed Web of Science ®Google Scholar
• ROSANO GM, AVERSA A, VITALE C, FABBRI A, FINI M, SPERA G: Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur. Urol. (2005) 47(2):214-220; discussion 220-222.
   PubMed Web of Science ®Google Scholar
• GIULIANO F: et al. Erectile dysfunction in patients with diabetes and/or hypertension. Eur. J. Int. Med. (2001) 12:240.
   Google Scholar
• KIM N, AZADZOI KM, GOLDSTEIN I, SAENZ DE TEJADA IS: A nitric oxide like factor mediates nonadrenergic neurogenic relaxation of penile corpus cavernosum smooth muscle. J. Clin. Invest. (1991) 88:112-118.
   PubMed Web of Science ®Google Scholar
• BIVALACQUA TJ, BURNETT AL, HELLSTROM WJ, CHAMPION HC: Overexpression of arginase in the aged mouse penis impairs erectile function and decreases eNOS activity: influence of in vivo gene therapy of anti-arginase. Am. J. Physiol. Heart Circ. Physiol. (2007) 292(3):H1340-H1351.
   PubMed Web of Science ®Google Scholar
• BIVALACQUA TJ, HELLSTROM WJG, KADOWITZ PJ, CHAMPION HC: Increased expression of arginase II in human diabetic corpus cavernousm: in diabetic associated erectile dysfunction. Biochem. Biophys. Res. Commun. (2001) 283:923-927.
   PubMed Web of Science ®Google Scholar
• BURNETT AL: Nitric oxide in the penis: physiology and pathology. J. Urol. (1997) 157:320-334.
   PubMed Web of Science ®Google Scholar
• JIAAN D B, SEFTEL A D, FOGARTY J et al.: Age-related increase in an advanced glycation end product in penile tissue. World J. Urol. (1995) 13:369-375.
   PubMed Web of Science ®Google Scholar
• SAENZ DE TEJADA I, GOLDSTEIN I, AZADZOI K, KRANE RJ, COHEN RA: Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N. Engl. J. Med. (1989) 320(16):1025-1030.
   PubMed Web of Science ®Google Scholar
• PICKARD RS, KING P, ZAR MA, POWELL PH: Corpus cavernosal relaxation in impotent men. Br. J. Urol. (1994) 74(4):485-491.
   PubMedGoogle Scholar
• KNISPEL HH, GOESSL C, BECKMANN R: Effects of papaverine and prostaglandin E1 on corpus cavernosum smooth muscle of arteriogenically and diabetically impotent men. Eur. Urol. (1994) 26(1):35-39.
   PubMed Web of Science ®Google Scholar
• SULLIVAN ME, BELL CR, DASHWOOD MR et al.: Autoradiographic localization of nitric oxide synthase binding sites in normal and diabetic rat corpus cavernosum. Eur. Urol. (1996) 30(4):506-511.
   PubMed Web of Science ®Google Scholar
• SULLIVAN ME, DASHWOOD MR, THOMPSON CS, MUDDLE JR, MIKHAILIDIS DP, MORGAN RJ: Alterations in endothelin B receptor sites in cavernosal tissue of diabetic rabbits: potential relevance to the pathogenesis of erectile dysfunction. J. Urol. (1997) 158(5):1966-1972.
   PubMed Web of Science ®Google Scholar
• FRANCAVILLA S, PROPERZI G, BELLINI C, MARINO G, FERRI C, SANTUCCI A: Endothelin-1 in diabetic and non-diabetic men with erectile dysfunction. J. Urol. (1997) 158:1770-1774.
   PubMed Web of Science ®Google Scholar
• MORANO S, GATTI A, MANDOSI E et al.: Circulating monocyte oxidative activity is increased in patients with Type 2 diabetes and erectile dysfunction. J. Urol. (2007) 177(2):655-659.
   PubMed Web of Science ®Google Scholar
• MCMILLAN DE: Development of vascular complications in diabetes. Vasc. Med. (1997) 2(2):132-142.
   PubMedGoogle Scholar
• MORELAND RB, HUANG Y, GOLDSTEIN I et al.: Inhibition of TGF-1-induced collagen synthesis in human corpus cavernosum smooth muscle by cAMP. Int. J. Impot. Res. (1996) 8:102 (Abstract 14).
   Web of Science ®Google Scholar
• AVERSA A, BASCIANI S, VISCA P et al.: Platelet-derived growth-factor (PDGF) and PDGF-receptors in rat corpus cavernosum: changes in expression after transient in vivo hypoxia. J. Endocrinol. (2001) 170:395-402.
   PubMed Web of Science ®Google Scholar
• WANG CJ, SHEN SY, WU CC, CHIANG CP: Penile blood flow study in diabetic impotence. Urol. Int. (1993) 50:209-212.
   PubMed Web of Science ®Google Scholar
• AKOI I, SHIMOYAMA K, AKOI N et al.: Platelet dependent thrombin generation in patients with diabetes mellitus: effects of glycaemic control on coagulability in diabetes. J. Am. Coll. Cardiol. (1996) 27:560-566.
   PubMed Web of Science ®Google Scholar
• CONLAN NG, FOLSOM AR, FINCH A et al.: Association of Factor VIII and Von Willebrand factor with age, race, sex and risk factors fo atherosclerosis. Thromb. Haemost. (1993) 70:380-385.
   PubMed Web of Science ®Google Scholar
• ITALIANO G, PETRELLI L, MARIN A et al.: Ultrastructural analysis of the cavernous and dorsal penile nerves in experimental diabetes. Int. J. Impotence Res. (1993) 5:149-160.
   PubMed Web of Science ®Google Scholar
• MERSDORF A, GOLDSMITH PC, DIEDERICHS N et al.: Ultrastructural changes in impotent penile tissue: a comparison of 65 patients. J. Urol. (1991) 145:749-758.
   PubMed Web of Science ®Google Scholar
• LINCOLN J, CROWE R, BLACKLAY PF et al.: Changes in the Vipergic, cholinergic and adrenergic innervation of human penile tissue in diabetic and non-diabetic impotent males. J. Urol. (1987) 137:1053-1059.
   PubMed Web of Science ®Google Scholar
• WELLMER A, SHARIEF MK, KNOWLES CH et al.: Quantitative sensory and autonomic testing in male diabetic patients with erectile dysfunction. BJU Int. (1999) 83(1):66-70.
   PubMed Web of Science ®Google Scholar
• SHABSIGH R, RAJFER J, AVERSA A et al.: The evolving role of testosterone in the treatment of erectile dysfunction. Int. J. Clin. Pract. (2006) 60(9):1087-1092.
   PubMed Web of Science ®Google Scholar
• MILLS TM, REILLY CM, LEWIS RW: Androgens and penile erection: a review. J. Androl. (1996) 17:633-638.
   PubMed Web of Science ®Google Scholar
• CORONA G, MANNUCCI E, PETRONE L et al.: Association of hypogonadism and Type II diabetes in men attending an outpatient erectile dysfunction clinic. Int. J. Impot. Res. (2006) 18(2):190-197.
   PubMed Web of Science ®Google Scholar
• RHODEN EL, RIBEIRO EP, TELOKEN C, SOUTO CA: Diabetes mellitus is associated with subnormal serum levels of free testosterone in men. BJU Int. (2005) 96(6):867-870.
   PubMed Web of Science ®Google Scholar
• GUAY AT: Sexual dysfunction in the diabetic patient. Int. J. Impotence Res. (2001) 13(Suppl. 5):S47-S50.
   Web of Science ®Google Scholar
• AVERSA A, ISIDORI AM, DE MARTINO MU et al.: Androgens and penile erection: evidence for a direct relationship between free testosterone and cavernous vasodilation in men with erectile dysfunction. Clin. Endocrinol. (2000) 53:517-522.
   PubMed Web of Science ®Google Scholar
• AVERSA A, ISIDORI AM, SPERA G, LENZI A, FABBRI A: Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. (2003) 58:632-638.
   PubMed Web of Science ®Google Scholar
• ZHANG XH, FILIPPI S, MORELLI A et al.: Testosterone restores diabetes-induced erectile dysfunction and sildenafil responsiveness in two distinct animal models of chemical diabetes. J. Sex Med. (2006) 3:253-266.
   PubMed Web of Science ®Google Scholar
• WATKINS SE, WILLIAMS P, RYDER KE, BONSHIER W: Psychometric assessment of diabetic impotence. Br. J. Psychiatry (1993) 162:840-842.
   PubMed Web of Science ®Google Scholar
• LIN C-S, XIN ZC, LIN G, LUE TF: Phosphodiesterases as therapeutic targets. Urology (2003) 61:685-691.
   PubMed Web of Science ®Google Scholar
• BISCHOFF E: Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. (2004) 16(Suppl. 1):S11-S4.
   PubMedGoogle Scholar
• JEON YH, HEO YS, KIM CM et al.: Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol. Life Sci. (2005) 62(11):1198-1220.
   PubMed Web of Science ®Google Scholar
• LIN CS, LIN G, XIN ZC, LUE TF: Expression, distribution and regulation of phosphodiesterase 5. Curr. Pharm. Des. (2006) 12(27):3439-3457.
   PubMed Web of Science ®Google Scholar
• AVERSA A, BRUZZICHES R, PILI M, SPERA G: Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr. Pharm. Des. (2006) 12(27):3467-3484.
   PubMed Web of Science ®Google Scholar
• PADMA-NATHAN H, GIULIANO F: Oral drug therapy for erectile dysfunction. Urol. Clin. North Am. (2001) 28:321-334.
   PubMed Web of Science ®Google Scholar
• PADMA-NATHAN H, STECHER VJ, ORAZEM J, TSENG L-J, DERIESTHAL H: Assessment of minimum time to onset of erection after Viagra (sildenafil citrate): results of a randomized, double-blind, placebocontrolled trial. Prog. Urol. (2003) 13(3 Suppl. 2):51.
   Google Scholar
• SEFTEL AD: Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin. Cardiol. (2004) 27(4 Suppl. 1):I14-I19.
   PubMed Web of Science ®Google Scholar
• SUPURAN CT, MASTROLORENZO A, BARBARO G, SCOZZAFAVA A: Phosphodiesterase 5 inhibitors – drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. Curr. Pharm. Des. (2006) 12(27):3459-3467.
   PubMed Web of Science ®Google Scholar
• BARBARO G, SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr. Pharm. Des. (2005) 11:1805-1843.
   PubMed Web of Science ®Google Scholar
• DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic–pharmacodinamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. (2000) 38(1):41-57.
   PubMed Web of Science ®Google Scholar
• CARSON CC, LUE TF: Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int. (2005) 96:257-280.
   PubMed Web of Science ®Google Scholar
• KLONER RA, HUTTER AM, EMMICK JT, MITCHELL MI, DENNE J, JACKSON G: Time course of the interaction between tadalafil and nitrates. J. Am. Coll. Cardiol. (2003) 42:1855-1860.
   PubMed Web of Science ®Google Scholar
• KLONER RA, BROWN M, PRISANT LM, COLLINS M; for the SILDENAFIL STUDY GROUP: Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am. J. Hypertens. (2001) 14:70-73.
   PubMed Web of Science ®Google Scholar
• CASTRO MM, RIZZI E, RASCADO RR, NAGASSAKI S, BENDHACK LM, TANUS-SANTOS JE: Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur. J. Pharmacol. (2004) 498(1-3):189-194.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ CA: Sildenafil–simvastatin interaction: possible cause of rhabdomyolysis? Am. Fam. Physician (2001) 63(4):636-637.
   PubMed Web of Science ®Google Scholar
• CARSON CC: Sildenafil: a 4-year update in the treatment of 20 million erectile dysfunction patients. Curr. Urol. Rep. (2003) 4(6):488-496.
   PubMedGoogle Scholar
• DEBUSK RF, PEPINE CJ, GLASSER DB, SHPILSKY A, DERIESTHAL H, SWEENEY M: Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. Am. J. Cardiol. (2004) 93(2):147-153.
   PubMed Web of Science ®Google Scholar
• SUNWOO S, KIM YS, CHO BL et al.: Post-marketing surveillance study of the safety and efficacy of sildenafil prescribed in primary care to erectile dysfunction patients. Int. J. Impot. Res. (2005) 17(1):71-75.
   PubMed Web of Science ®Google Scholar
• ARRUDA-OLSON AM, MAHONEY DW, NEHRA A, LECKEL M, PELLIKKA PA: Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease: a randomized crossover trial. JAMA (2002) 287(6):719-725.
   PubMed Web of Science ®Google Scholar
• KLONER RA: Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am. J. Med. (2000) 109(Suppl. 9A):13S-21S.
   PubMedGoogle Scholar
• KOSTIS JB, JACKSON G, ROSEN R et al.: Sexual dysfunction and cardiac risk (The Second Princeton Consensus Conference). Am. J. Cardiol. (2005) 96:313-321.
   PubMed Web of Science ®Google Scholar
• RASHID A: The efficacy and safety of PDE5 inhibitors. Clin. Cornerstone (2005) 7:47-56.
   PubMedGoogle Scholar
• ZHANG X, FENG Q, COTE RH: Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (pde6) in retinal photoreceptors. Invest. Ophthalmol. Vis. Sci. (2005) 46:3060-3066.
   PubMed Web of Science ®Google Scholar
• LATIES AM, ZRENNER E: Viagra (sildenafil citrate) and ophthalmology. Prog. Ret. Eye Res. (2002) 21:485-506.
   PubMed Web of Science ®Google Scholar
• CUNNINGHAM AV, SMITH KH: Anterior ischemic optic neuropathy associatedwith Viagra. J. Neuroophthalmol. (2001) 21:22-25.
   PubMed Web of Science ®Google Scholar
• ESCARAVAGE GK, WRIGHT JD, GIVRE SJ: Tadalafil associated with anterior ischemic optic neuropathy. Arch. Ophthalmol. (2005) 123:399-400.
   PubMed Web of Science ®Google Scholar
• POMERANZ HD, SMITH KH, HART WM et al.: Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology (2002) 109:584-587.
   PubMed Web of Science ®Google Scholar
• THE ISCHEMIC OPTIC NEUROPATHY DECOMPRESSION TRIAL RESEARCH GROUP: Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. Arch. Ophthalmol. (1996) 114:1366-1374.
   PubMed Web of Science ®Google Scholar
• RUCKER JC, BIOUSSE V, NEWMAN NJ: Ischemic optic neuropathies. Curr. Opin. Neurol. (2004) 17:27-35.
   PubMed Web of Science ®Google Scholar
• FELDMAN HA, JOHANNES CB, DERBY CA et al.: Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Prev. Med. (2000) 30:328-338.
   PubMed Web of Science ®Google Scholar
• ROUMEGUERE T, WESPES E, CARPENTIER Y et al.: Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur. Urol. (2003) 44:355-369.
   PubMed Web of Science ®Google Scholar
• GORKIN L, HVIDSTEN K, SOBEL RE, SIEGEL R: Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy. Int. J. Clin. Pract. (2006) 60(4):500-503.
   PubMed Web of Science ®Google Scholar
• BANERJEE A, LOCKE-WINTER CR, ROGERS KB et al.: Preconditioning against myocardial dysfunction after ischemia and reperfusion by an α-1 adrenergic mechanism. Circ. Res. (1993) 73:656-670.
   PubMed Web of Science ®Google Scholar
• SCHULTZ JE, HSU AK, GROSS GJ: Ischemic preconditioning in the intact rat heart is mediated by δ1- but not μ- or κ-opioid receptors. Circulation (1997) 97:1282-1289.
   Web of Science ®Google Scholar
• TRITTO I, D’ANDREA D, ERAMO N et al.: Oxygen radicals can induce preconditioning in rabbit hearts. Circ. Res. (1997) 80:743-748.
   PubMed Web of Science ®Google Scholar
• WALL TM, SHEEHY R, HARTMAN JC: Role of bradykinin in myocardial preconditioning. J. Pharmacol. Exp. Ther. (1994) 270:681-689.
   PubMed Web of Science ®Google Scholar
• FRYER RM, HSU AK, EELLS JT, NAGASE H, GROSS GJ: Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ. Res. (1999) 99:846-851.
   Google Scholar
• ZHAO TC, XI L, CHELLIAH J, LEVASSEUR JE, KUKREJA RC: Inducible nitric oxide synthase mediates delayed myocardial protection induced by activation of adenosine A1 receptors: evidence from gene-knockout mice. Circulation (2000) 102:902-907.
   PubMed Web of Science ®Google Scholar
• ZHAO TC, KUKREJA RC: Late preconditioning elicited by activation of adenosine A3 receptor in heart: role of NFjB, iNOS and mitochondrial KATP channel. J. Mol. Cell Cardiol. (2002) 34:263-277.
   PubMed Web of Science ®Google Scholar
• LAUDE K, BEAUCHAMP P, THUILLEZ C, RICHARD V: Endothelial protective effects of preconditioning. Cardiovasc. Res. (2002) 55:466-473.
   PubMed Web of Science ®Google Scholar
• MANKAD PS, AMRANI M, ROTHERY S, SEVERS NJ, YACOUB MH: Relative susceptibility of endothelium and myocardial cells to ischaemia–reperfusion injury. Acta Physiol. Scand. (1997) 161:103-112.
   PubMedGoogle Scholar
• KHARBANDA RK, PETERS M, WALTON B et al.: Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation (2001) 103:1624-1630.
   PubMed Web of Science ®Google Scholar
• TOMAI F, CREA F, CHIARIELLO L, GIOFFRE PA: Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation (1999) 100:559-563.
   PubMedGoogle Scholar
• VARDIA A, BULUSB M, REISNERB S et al.: Effects of sildenafil citrate (Viagra®) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. Eur. Urol. (2003) 43:544-551.
   PubMed Web of Science ®Google Scholar
• GORI T, SICURO S, DRAGONI S, DONATI G, FORCONI S, PARKER JD: Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate–sensitive potassium channels: a human in vivo study. Circulation (2005) 111:742-746.
   PubMed Web of Science ®Google Scholar
• HALCOX JP, NOUR KR, ZALOS G et al.: The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J. Am. Coll. Cardiol. (2002) 40:1232-1240.
   PubMed Web of Science ®Google Scholar
• KUKREJA RC, SALLOUM F, DAS A et al.: Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications. Vascul. Pharmacol. (2005) 42:219-232.
   PubMed Web of Science ®Google Scholar
• DAS A, XI L, KUKREJA RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J. Biol. Chem. (2005) 280:12944-12955.
   PubMed Web of Science ®Google Scholar
• WALLIS RM, CORBIN JD, FRANCIS SH, ELLIS P: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83(5A):3C-12C.
   PubMed Web of Science ®Google Scholar
• KUKREJA RC, OCKAILI R, SALLOUM F, YIN C, HAWKINS J, DAS A, XI L: Cardioprotection with phosphodiesterase-5 inhibition-a novel preconditioning strategy. J. Mol. Cell Cardiol. (2004) 36(2):165-173.
   PubMed Web of Science ®Google Scholar
• DEVAN BD, SIERRA-MERCADO D Jr, JIMENEZ M et al.: Phosphodiesterase inhibition by sildenafil citrate attenuates the learning impairment induced by blockade of cholinergic muscarinic receptors in rats. Pharmacol. Biochem. Behav. (2004) 79(4):691-699.
   PubMed Web of Science ®Google Scholar
• GAZZARUSO C, GIORDANETTI S, DE AMICI E et al.: Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated Type 2 diabetic patients. Circulation (2004) 110:1-5.
   Google Scholar
• YAVUZGIL O, ALTAY B, ZOGHI M, GURGUN C, KAYIKCIOGLU M, KULTURSAY H: Endothelial function in patients with vasculogenic erectile dysfunction. Int. J. Cardiol. (2005) 103(1):19-26.
   PubMed Web of Science ®Google Scholar
• HURT KJ, MUSICKI B, PALESE MA et al.: Akt-dependent phosphorylation of endothelial nitric-oxide synthase mediates penile erection. Proc. Natl. Acad. Sci. USA (2002) 99:4061-4066.
   PubMed Web of Science ®Google Scholar
• EL GALLEY R, RUTLAND H, TALIC R, KEANE T, CLARK H: Long-term efficacy of sildenafil and tachyphylaxis effect. J. Urol. (2001) 166:927-931.
   PubMed Web of Science ®Google Scholar
• CARSON CC, BURNETT AL, LEVINE LA, NEHRA A: The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology (2002) 60:12-27.
   PubMed Web of Science ®Google Scholar
• CHRISTIANSEN E, GUIRGUIS WR, COX D, OSTERLOH IH: Long-term efficacy and safety of oral Viagra (sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal. Int. J. Impot. Res. (2000) 12:177-182.
   PubMed Web of Science ®Google Scholar
• DESOUZA C, PARULKAR A, LUMPKIN D, AKERS D, FONSECA VA: Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in Type 2 diabetes. Diabetes Care (2002) 25:1336-1339.
   PubMed Web of Science ®Google Scholar
• MONTORSI F, MAGA T, STRAMBI LF et al.: Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology (2000) 56:906-911.
   PubMed Web of Science ®Google Scholar
• LIN G, XIN ZC, LUE TF, LIN CS: Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism. J. Urol. (2003) 170:S15-S18.
   PubMed Web of Science ®Google Scholar
• MUSICKI B, CHAMPION HC, BECKER RE, LIU T, KRAMER MF, BURNETT AL: Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol. Pharmacol. (2005) 68(1):226-232.
   PubMed Web of Science ®Google Scholar
• AYALA JE, BRACY DP, JULIEN BM, ROTTMAN JN, FUEGER PT, WASSERMAN DH: Chronic treatment with sildenafil improves energy balance and insulin action in high fat-fed conscious mice. Diabetes (2007) 56(4):1025-1033.
   PubMed Web of Science ®Google Scholar
• PEGGE NG, TWOMEY AM, VAUGHTON K, GRAVENORT MB, RAMSEY MW, PRICE DE: The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet. Med. (2006) 23:873-878.
   PubMed Web of Science ®Google Scholar
• KATZ SD, BALIDEMAJ K, HOMMA S, WU H, WANG J, MAYBAUM S: Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J. Am. Coll. Cardiol. (2000) 36:845-851.
   PubMed Web of Science ®Google Scholar
• CALLES-ESCANDON J, CIPOLLA M: Diabetes and endothelial dysfunction: a clinical perspective. Endocr. Rev. (2001) 22:36-52.
   PubMed Web of Science ®Google Scholar
• SOMMER F, KLOTZ T, ENGELMANN U: Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial. Asian J. Androl. (2007) 9(1):134-141.
   PubMed Web of Science ®Google Scholar
• SHAKIR SA, WILTON LV, BOSHIER A, LAYTON D, HEELEY E: Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. Br. Med. J. (2001) 322:651-652.
   PubMed Web of Science ®Google Scholar
• JACKSON G: Phosphodiesterase 5 inhibition: effects on the coronary vasculature. Int. J. Clin. Pract. (2001) 55:183-188.
   PubMed Web of Science ®Google Scholar
• HERRMANN HC, CHANG G, KLUGHERZ BD, MAHONEY PD: Hemodynamic effects of sildenafil in men with severe coronary artery disease. N. Engl. J. Med. (2000) 342:1622-1626.
   PubMed Web of Science ®Google Scholar
• AVERSA A, ROSANO G, VITALE C, VOLTERRANI M, FINI M, SPERA G: Effects of chronic sildenafil therapy on endothelial function in diabetic patients. 7th Meeting of European Society for Sexual Medicine, London, 5 – 8 December 2004. J. Sex Med. (2004) 2(Suppl. 1):20.
   Google Scholar
• GALIÈ N, GHOFRANI HA, TORBICKI A et al.: Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157.
   PubMed Web of Science ®Google Scholar
• TAKIMOTO E, CHAMPION HC, LI M et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. (2005) 11(2):214-222.
   PubMed Web of Science ®Google Scholar
• GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three p-5 Inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44:1488-1496.
   PubMed Web of Science ®Google Scholar
• PINKNEY JH, STEHOUWER CD, COPPACK SW, YUDKIN JS: Endothelial dysfunction: cause of the insulin resistance syndrome. Diabetes (1997) 46(Suppl. 2):S9-S13.
   PubMed Web of Science ®Google Scholar
• JACKSON G, MONTORSI P, CHEITLIN MD: Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. Urology (2006) 68(3 Suppl.):47-60.
   PubMed Web of Science ®Google Scholar